Amicus Therapeutics (FOLD)
(Delayed Data from NSDQ)
$10.56 USD
-0.03 (-0.28%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $10.56 0.00 (0.00%) 4:18 PM ET
3-Hold of 5 3
D Value A Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$10.56 USD
-0.03 (-0.28%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $10.56 0.00 (0.00%) 4:18 PM ET
3-Hold of 5 3
D Value A Growth A Momentum A VGM
Zacks News
Amicus (FOLD) Stock Down on Q3 Earnings and Revenue Miss
by Zacks Equity Research
Amicus (FOLD) misses both Q3 earnings and revenue estimates. Resultantly, the stock price falls.
Kodiak Sciences (KOD) Q3 Loss Widens, Eye Candidate in Focus
by Zacks Equity Research
Kodiak Sciences (KOD) reports wider-than-expected loss for the third quarter of 2021. Pipeline development remains in focus for the company.
Editas (EDIT) Q3 Earnings Beat Estimates, Revenues Fall Y/Y
by Zacks Equity Research
Editas (EDIT) reports narrower-than-expected loss in the third quarter of 2021 while its revenues marginally beat estimates. Focus remains on the development of lead candidate, EDIT-101.
Apellis' (APLS) Q3 Loss Widens, Revenues Surpass Estimates
by Zacks Equity Research
Apellis (APLS) reports wider-than-expected loss for the third quarter of 2021 while revenues surpass expectations.
Amicus Therapeutics (FOLD) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of -5.56% and -2.30%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Immunovant (IMVT) Reports Wider-Than-Expected Loss in Q2
by Zacks Equity Research
Immunovant's (IMVT) earnings miss estimates in second-quarter fiscal 2022 (ended Sep 30, 2021). Focus remains on lead pipeline candidate IMVT-1401.
Viatris (VTRS) Beats on Q3 Earnings & Sales, Tweaks View
by Zacks Equity Research
Viatris (VTRS) beats on Q3 earnings and sales. The company raises the lower end of its annual revenue guidance.
Global Blood's (GBT) Earnings & Revenues Lag Estimates in Q3
by Zacks Equity Research
Global Blood (GBT) reports wider-than-expected loss in the third quarter of 2021 while its revenues miss estimates.
Endo (ENDP) Beats Q3 Earnings & Sales Estimates, Raises View
by Zacks Equity Research
Endo (ENDP) tops third-quarter earnings and sales estimates and raises its forecast. Shares are up in pre-market trading.
Horizon's (HZNP) Q3 Earnings Beat Estimates, 2021 Guidance Up
by Zacks Equity Research
Horizon's (HZNP) earnings and revenues beat estimates in the third quarter of 2021. The company lifts net sales guidance for 2021.
Sarepta (SRPT) Q3 Earnings Beat, 2021 Sales View Raised
by Zacks Equity Research
Strong demand for Sarepta's (SRPT) DMD drugs boosts its top line in the third quarter. The company also raises revenues guidance for the year. Stock up in after-market trading.
Ultragenyx's (RARE) Q3 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Ultragenyx (RARE) reports narrower-than-expected loss in the third quarter of 2021 while revenues surpass estimates.
Bausch's (BHC) Q3 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Bausch (BHC) beats on earnings but misses on sales in the third quarter. The company reiterates annual revenue guidance.
Dr. Reddy's (RDY) Q2 Earnings, Sales Increase Year Over Year
by Zacks Equity Research
Dr. Reddy's (RDY) earnings and revenues increase year over year in second-quarter fiscal 2022.
Will Amicus Therapeutics (FOLD) Report Negative Q3 Earnings? What You Should Know
by Zacks Equity Research
Amicus Therapeutics (FOLD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BioMarin (BMRN) Beats on Q3 Earnings, Ups 2021 Guidance
by Zacks Equity Research
BioMarin's (BMRN) earnings beat estimates in the third quarter of 2021 while revenues miss the same. The company raises total revenue guidance and increases adjusted earnings guidance for 2021.
Can Amicus Therapeutics (FOLD) Climb 77% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 77.1% upside potential for Amicus Therapeutics (FOLD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Galera (GRTX) Tanks As Oral Mucositis Study Fails to Meet Goal
by Zacks Equity Research
Galera's (GRTX) phase III ROMAN study on avasopasem for treating radiotherapy-induced severe oral mucositis in patients with head and neck cancer fails to meet its primary endpoint. Shares fall.
Radius' (RDUS) Study on Tymlos for Osteoporosis in Men Meets Goal
by Zacks Equity Research
Radius (RDUS) reports positive top-line results from the ATOM study evaluating Tymlos (abaloparatide) subcutaneous injection for use in men with osteoporosis. The study met the primary endpoint.
Oyster Point's (OYST) Tyrvaya Gets FDA Nod for Dry Eye Disease
by Zacks Equity Research
The FDA approves Oyster Point's (OYST) Tyrvaya nasal spray for the treatment of the signs and symptoms of dry eye disease.
Bristol Myers (BMY) Gets Positive CHMP Opinion for Zeposia in UC
by Zacks Equity Research
The CHMP gives a positive opinion on, and recommends granting approval to Bristol Myers' (BMY) Zeposia for the treatment of adults with moderately to severely active ulcerative colitis.
Wall Street Analysts Predict a 59% Upside in Amicus Therapeutics (FOLD): Here's What You Should Know
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 59.3% in Amicus Therapeutics (FOLD). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Amcius (FOLD) to Spin-Off Gene Therapy Arm, Form New Firm With ARYA
by Zacks Equity Research
Amicus (FOLD) plans to separate its gene therapy business into a new company formed in alliance with ARYA Sciences Acquisition Corp.
Sanofi (SNY) Pompe Disease Drug Receives FDA's Approval
by Zacks Equity Research
The FDA gives approval to Sanofi's (SNY) Nexviazyme (avalglucosidase alfa) for treating late-onset Pompe disease.
Amicus (FOLD) Q2 Earnings & Revenues Top Estimates, Stock Up
by Zacks Equity Research
Amicus (FOLD) reports narrower-than-expected Q2 loss. The sales figure also beat estimates. Following encouraging results and positive progress with pipeline candidates, the stock rises.